Year: 2026
Type: article
Abstract: Introduction Thrombotic microangiopathy (TMA) is characterized by the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Complement inhibition with eculizumab is highly efficacious in TMA secondary to complement dysregulation. However, a growing number of eculizumab-nonresponsive TMAs are reported. Recently, a syndromic form of TMA due to recessive variants in RNA exosome components ( EXOSC3 and EXOSC5 ) has been identified. The underlying pathogenesis remains unclear. Methods We identified 34 children across Europe with pontocerebellar hypoplasia 1b (PCH1b) due to EXOSC3 rare variants and reviewed their clinical history for signs of TMA. To further examine the pathogenesis, a tamoxifen-inducible whole-body Exosc3 conditional knockout mouse model ( Exosc3 KO ) was used. Results Thirteen (eight male, five female) cases of EXOSC3-TMA were identified. In the United Kingdom, the incidence of EXOSC3-TMA was 0.004/million/year. Three children received long-term eculizumab therapy: one child failed to respond and two relapsed on treatment. Exosc3 KO demonstrated cell-cycle arrest and apoptosis resulting in death in a median of eight days, with sequelae noted in actively dividing cells in the bone marrow and large intestine. In this timeframe, no kidney pathology was identified. Conclusions EXOSC3-TMA is a severe, early-onset, C5 inhibitor–resistant TMA. EXOSC3-TMA should be considered in eculizumab-resistant pediatric TMA, particularly in the context of neurodevelopmental disease.
Source: Kidney International
Authors: Patrick R. Walsh, Uttiya Basu, Tahsin Stefan Barakat, Bodo B. Beck, Enrico Bertini, Vicky Brocklebank, Nuno Corderio, Jasmina Ćomić, Nora Abazi-Emini, Joel Fluss, Annette George, Marcus Bülow, Beth G. Gibson, Sophie Hambleton, Julia Hoefele, David Hunt, Ivan Ivanov, Sally Johnson, Urania Kotzaeridou, Jana Laštůvková, Andrew Lunn, Grace Mallett, Isabel Pappworth, Helen Philippou, Konrad Platzer, Julie Robson, Dana Šafka brožková, Kate Smith-Jackson, Manish D. Sinha, Gemma Thompson, Katrina Wood, Ginevra Zanni, Zoltán Prohászka, Jana Laubova, Judit Aranka, Zsüliet Bojtár, Violetta Antal-Konya, Cristina Bologa, Vasiliki Karava, Thessalia Kamilari, Elissavet Georgiadou, Velibor Tasic, Petya Markova, Kevin J. Marchbank, David Kavanagh
Institutions: Newcastle University, Columbia University, Erasmus MC, University of Cologne, University Hospital Cologne, Bambino Gesù Children's Hospital, NHS Ayrshire and Arran, Institut für Humangenetik, Technical University of Munich, Ss. Cyril and Methodius University in Skopje, University Hospital of Geneva, Charité – Universitätsmedizin Berlin, Ludwig-Maximilians-Universität München, Institute of Genetics and Cancer, University of Edinburgh, Medical University Plovdiv, University Hospital Heidelberg, Nottingham University Hospitals NHS Trust, University of Leeds, University Hospital Leipzig, Leipzig University, Charles University, King's College London, Guy's and St Thomas' NHS Foundation Trust, Evelina London Children's Healthcare, Royal Victoria Infirmary, Semmelweis University, Jan Evangelista Purkyně University in Ústí nad Labem, Hungarian Academy of Sciences, Spitalului Clinic de Urgență pentru Copii Maria Sklodowska Curie, National and Kapodistrian University of Athens, Children's Hospital Agia Sophia
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,500
Awards: G4864086082, G6599345524
OpenAlex ID: W7170035673
